Home › Medicines › Survanta
বাংলায় দেখুন
Survanta

Survanta

Intratracheal Suspension

🧬 Phospholipids 🏢 AbbVie Inc. USA
Generic Name Phospholipids
Strength 25 mg/ml
Manufacturer AbbVie Inc. USA
Unit Price 4 ml vial: ৳ 37,800.00

🔹 Indications

🔹 Dosage & Administration

For Intratracheal Administration Only. Survanta should be administered by or under the supervision of clinicians experienced in intubation, ventilator management and general care of premature infants.

Marked improvements in oxygenation may occur within minutes of administration of Survanta. Therefore, frequent and careful clinical observation and monitoring of systemic oxygenation are essential to avoid hyperoxia.

Each dose of Survanta is 100 mg of phospholipid/kg birth weight (4 mL/kg). The Survanta Dosage Chart shows the total dosage for a range of birth weights.

Four doses of Survanta can be administered in the first 48 hours of life. Doses should be given no more frequently than every 6 hours.

🔹 Side Effects

  • Respiratory: lung consolidation, blood from the endotracheal tube, deterioration after weaning, respiratory decompensation, subglottic stenosis, paralyzed diaphragm, respiratory failure.
  • Cardiovascular: hypotension, hypertension, tachycardia, ventricular tachycardia, aortic thrombosis, cardiac failure, cardio-respiratory arrest, increased apical pulse, persistent foetal circulation, air embolism, total anomalous pulmonary venous return.
  • Gastrointestinal: abdominal distension, haemorrhage, intestinal perforations, volvulus, bowel infarct, loading intolerance, hepatic failure, stress ulcer.
  • Renal: renal failure, haematuria.
  • Haematologic: coagulopathy, thrombocytopenia, disseminated intravascular coagulation
  • Central Nervous System: seizures.
  • Endocrine/Metabolic: adrenal haemorrhage, inappropriate ADH secretion, hyperphosphataemia.
  • Musculoskeletal: inguinal hernia.
  • Systemic: fever, deterioration.

🔹 Precautions & Warnings

Survanta are intended for intratracheal use only. Survanta can rapidly affect oxygenation and lung compliance. Therefore, its use should be restricted to a highly supervised clinical setting with immediate availability of clinicians experienced with intubation, ventilator management and general care of premature infants. Infants receiving Survanta should be frequently monitored with arterial or transcutaneous measurement of systemic oxygen and carbon dioxide.

During the dosing procedure, transient episodes of bradycardia and decreased oxygen saturation have been reported.  If these occur, stop the dosing procedure and initiate appropriate measures to alleviate the condition. After stabilization, resume the dosing procedure.

General: Rales and moist breath sounds can occur transiently after administration. Endotracheal suctioning or other remedial action is not necessary unless clear-cut signs of airway obstruction are present.

Increased probability of post-treatment nosocomial sepsis in Survanta-treated infants was observed in the controlled clinical trials (See Table). The increased risk for sepsis among Survanta-treated infants was not associated with increased mortality among these infants. The causative organisms were similar in treated and control infants. There was no significant difference between groups in the rate of post-treatment infections other than sepsis.

Use of Survanta in infants less than 600 g birth weight or greater than 1750 g birth weight has not been evaluated in controlled trials. There is no controlled experience with use of Survanta in conjunction with experimental therapies for RDS (eg. high-frequency ventilation or extracorporeal membrane oxygenation).

No information is available on the effects of doses other than 100 mg Survantas / kg, more than four doses, dosing more frequently than every 6 hours, or administration after 48 hours of age.

🔹 Storage Conditions

Store unopened vials at refrigeration temperature (2-8°C). Protect from light. Store vials in carton until ready for use. Vials are for single use only.  Upon opening, discard unused drug.

🔍 People also search for

Survanta Survanta Intratracheal Suspension used for Survanta side effects Survanta price Survanta dose Survanta Intratracheal Suspension uses Is Survanta safe Survanta dosage Survanta alternative Survanta Bangladesh Phospholipids Phospholipids price Bangladesh Intratracheal Suspension price Bangladesh AbbVie Inc. USA medicine bd Survanta 25 mg/ml Survanta 25 mg/ml price

💡 Frequently Asked Questions

Survanta is indicated for prevention and treatment of Respiratory Distress Syndrome (RDS) (hyaline membrane disease) in premature infants.Prevention: In premature infants less than 1250 g birthweight, or with evidence of surfactant deficiency, give S...
For Intratracheal Administration Only. Survanta should be administered by or under the supervision of clinicians experienced in intubation, ventilator management and general care of premature infants.Marked improvements in oxygenation may occur withi...
Respiratory: lung consolidation, blood from the endotracheal tube, deterioration after weaning, respiratory decompensation, subglottic stenosis, paralyzed diaphragm, respiratory failure. Cardiovascular: hypotension, hypertension, tachycardia, vent...

User Reviews

⭐
No reviews yet!
Be the first to share your experience.

Write a Review